Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

@article{Bogenschutz2015PsilocybinassistedTF,
  title={Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study},
  author={Michael P. Bogenschutz and Alyssa A. Forcehimes and Jessica A Pommy and Claire E. Wilcox and Pcr Barbosa and Rick J. Strassman},
  journal={Journal of Psychopharmacology},
  year={2015},
  volume={29},
  pages={289 - 299}
}
Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Although recent studies have investigated the effects of psilocybin in various populations, there have been no studies on the efficacy of psilocybin for alcohol dependence. We conducted a single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data. Ten… Expand
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
TLDR
Preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression is provided and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach. Expand
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
TLDR
Describing treatment trajectories of three participants in the ongoing trial of psilocybin-assisted treatment of alcohol use disorder illustrates the range of experiences and persisting effects of pSilocybin treatment and draws several qualitative conclusions. Expand
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
TLDR
The results in the ADE model do not support the hypothesis that microdosing or high doses of psychedelic reduce relapse behavior, and it is not a translatable treatment option to give psychedelics sub-chronically for relapse prevention. Expand
Classic hallucinogens in the treatment of addictions
TLDR
A comprehensive review of both historical and recent clinical research on the use of classic hallucinogens in the treatment of addiction, selectively review other relevant research concerning hallucinogenic research, and suggest directions for future research are provided. Expand
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Research activity on the potential clinical value of classic hallucinogens and other psychedelics has increased markedly in the past two decades, and promises to continue to expand. ExperimentalExpand
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
TLDR
There is an enduring therapeutic effect in migraine headache after a single administration of psilocybin, urging further investigation into the mechanism underlying the clinical effects of select 5-HT 2A receptor compounds in migraine, as well as other neuropsychiatric conditions. Expand
Potential Therapeutic Effects of Psilocybin
Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus withinExpand
Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders
TLDR
Psilocybin-assisted therapy efficacy and safety appear promising, but more robust clinical trials will be required to support FDA approval and identify the potential role in clinical psychiatry. Expand
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
TLDR
The view that the quality of the acute psychedelic experience is a key mediator of long-term changes in mental health is bolstered, as data from a clinical trial assessing psilocybin for treatment-resistant depression confirmed this. Expand
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
  • E. Jacobs
  • Medicine
  • Journal of Psychedelic Studies
  • 2020
TLDR
Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
TLDR
An open-label pilot study administering moderate and high psilocybin doses within a structured 15-week smoking cessation treatment protocol demonstrated that 12 of 15 participants showed seven-day point prevalence abstinence at 6-month follow-up, substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies. Expand
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
TLDR
A clinical trial to evaluate abstinence outcomes in a population of prescription opioid abusers after exposure to one of three conditions: a drug-induced altered state using psilocybin, a non-drug- induced altered state via hyperventilation (Holotropic Breathwork), and an active placebo with niacin. Expand
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
TLDR
This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety. Expand
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
TLDR
Under supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Expand
Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
TLDR
It is suggested that headache is an adverse event to be expected with the nonmedical use of psilocybin-containing mushrooms as well as the administration of p silocybin in human research. Expand
Examining the psychological mechanisms of psilocybin-assisted smoking cessation treatment: A pilot study
TLDR
Bayesian dose finding is a novel, rational method for selecting doses to be used in outpatient trials that should utilize a 600mg dose of modafinil for MA dependence. Expand
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
TLDR
Research continues to explore which types of alcohol-dependent individual would benefit the most from treatment with naltrexone or acamprosate and other promising medications, as well as medication combinations, for treating alcohol dependence continue to be explored. Expand
Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial
TLDR
The results suggest that alcohol dependent subjects can show marked clinical improvement within a structured alcohol treatment program and do not support an important role for ritanserin in the treatment of alcohol dependence. Expand
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
TLDR
When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences. Expand
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
  • M. Mangini
  • Psychology, Medicine
  • Journal of psychoactive drugs
  • 1998
TLDR
The history of one branch of psychedelic research, the therapeutic use of LSD in the treatment of alcoholism, and of the events that led to the relabeling of the "hallucinogens" as drugs of abuse are explored. Expand
...
1
2
3
4
5
...